AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $554.0M, listed on NASDAQ, employing roughly 57 people, carrying a beta of 0.00 to the broader market. AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. Led by Tim Knotnerus, public since 2024-05-29.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for AGMB as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →